Intensity Therapeutics, Inc. (INTS)

NASDAQ: INTS · IEX Real-Time Price · USD

4.750

-0.100 (-2.06%)

At close: Jul 19, 2024, 4:30 PM

4.720

-0.030 (-0.63%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Intensity Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	4.98	3.53	2.42	2.16	1.17	1.24
Research & Development	6.83	4.79	5.13	5.86	5.05	4.44
Operating Expenses	11.81	8.32	7.55	8.01	6.22	5.68
Operating Income	-11.81	-8.32	-7.55	-8.01	-6.22	-5.68
Interest Expense / Income	0.22	0.31	0.08	0	0	0
Other Expense / Income	1.78	1.91	-0.05	-0.12	-0.19	-0.3
Pretax Income	-13.8	-10.54	-7.58	-7.9	-6.03	-5.38
Net Income	-13.8	-10.54	-7.58	-7.9	-6.03	-5.38
Preferred Dividends	1.32	1.32	0	0	0	0
Net Income Common	-15.13	-11.86	-7.58	-7.9	-6.03	-5.38
Shares Outstanding (Basic)	14	9	3	3	3	3
Shares Outstanding (Diluted)	14	9	3	3	3	3
Shares Change	302.03%	152.67%	-	0.02%	0.19%	-
EPS (Basic)	-2.06	-1.38	-2.22	-2.32	-1.76	-1.58
EPS (Diluted)	-2.06	-1.38	-2.22	-2.32	-1.76	-1.58
Free Cash Flow	-10.67	-7.21	-5.48	-6.83	-5.37	-4.42
Free Cash Flow Per Share	-0.78	-0.84	-1.61	-2.00	-1.57	-1.30
EBITDA	-13.53	-10.09	-7.32	-7.72	-5.91	-5.28
Depreciation & Amortization	0.05	0.15	0.18	0.17	0.12	0.1
EBIT	-13.58	-10.23	-7.5	-7.9	-6.03	-5.38

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).